Literature DB >> 16105000

Invasive optimization of cardiac resynchronization therapy: role of sequential biventricular and left ventricular pacing.

Klaus Kurzidim1, Heinrich Reinke, Johannes Sperzel, Hans Jürgen Schneider, Dejan Danilovic, Gregor Siemon, Thomas Neumann, Christian W Hamm, Heinz-Friedrich Pitschner.   

Abstract

BACKGROUND: Aim of this invasive study was to characterize and quantify changes in left ventricular (LV) systolic function due to sequential biventricular pacing (BV) as compared to right atrial triggered simultaneous BV (BV(0)), LV, and right ventricular (RV) pacing in patients with congestive heart failure (CHF).
METHODS: In 22 CHF patients, all in sinus rhythm, temporary multisite pacing was performed prior to implantation of a permanent system. LV systolic function was evaluated invasively by the maximum rate of LV pressure increase (dP/dt(max)). Sequential BV pacing was performed with preactivation of either ventricle at 20-80 ms.
RESULTS: In comparison to RV pacing, LV and BV(0) pacing increased dP/dt(max) by 33.9 +/- 19.3% and 34.0 +/- 22.6%, respectively (P < 0.001). In 9 patients, optimized sequential BV pacing further improved dP/dt(max) by 8.5 +/- 4.8% compared to BV(0) (range 3.3-17.1, P < 0.05). In 10 patients exhibiting a PR interval < or =200 ms, LV pacing was either superior (n = 6) or equal to BV(0) pacing (n = 4). In these 10 patients, LV pacing yielded a 7.4 +/- 8.0% higher dP/dt(max) than BV(0) pacing (P < 0.05).
CONCLUSIONS: Using sequential BV pacing, generally with LV preactivation, moderate improvements in LV systolic function can be achieved in selected patients. Baseline PR interval may aid in the selection of the optimum cardiac resynchronization therapy (CRT) mode, favoring LV pacing in patients with a PR interval < or =200 ms.

Entities:  

Mesh:

Year:  2005        PMID: 16105000     DOI: 10.1111/j.1540-8159.2005.00181.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  7 in total

1.  Optimization of cardiac resynchronization therapy after implantation.

Authors:  Ayesha Hasan; William T Abraham
Journal:  Curr Treat Options Cardiovasc Med       Date:  2008-08

2.  First-degree atrioventricular block. Clinical manifestations, indications for pacing, pacemaker management & consequences during cardiac resynchronization.

Authors:  S Serge Barold; Arzu Ilercil; Fabio Leonelli; Bengt Herweg
Journal:  J Interv Card Electrophysiol       Date:  2007-03-02       Impact factor: 1.900

3.  Midterm 'super-response' to cardiac resynchronization therapy by biventricular pacing with fusion: insights from electro-anatomical mapping.

Authors:  Radu Vatasescu; Antonio Berruezo; Lluis Mont; David Tamborero; Marta Sitges; Etel Silva; Jose María Tolosana; Bárbara Vidal; David Andreu; Josep Brugada
Journal:  Europace       Date:  2009-10-31       Impact factor: 5.214

4.  [CRT in atrial fibrillation--methodical and apparatus options in decision-making].

Authors:  B Ismer; T Körber; G H von Knorre; M Heinke; W Voss; K Werwick; C Melzer; C Butter; C A Nienaber
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2008-12

5.  Biophysical modeling to simulate the response to multisite left ventricular stimulation using a quadripolar pacing lead.

Authors:  Steven A Niederer; A K Shetty; G Plank; J Bostock; R Razavi; N P Smith; C A Rinaldi
Journal:  Pacing Clin Electrophysiol       Date:  2011-10-31       Impact factor: 1.976

6.  Relationship between intracardiac impedance and left ventricular contractility in patients undergoing cardiac resynchronization therapy.

Authors:  Matthew R Ginks; Elena Sciaraffia; Andreas Karlsson; John Gustafsson; Shoaib Hamid; Julian Bostock; Marcus Simon; Carina Blomström-Lundqvist; C Aldo Rinaldi
Journal:  Europace       Date:  2011-04-15       Impact factor: 5.214

7.  Echo-driven V-V optimization determines clinical improvement in non responders to cardiac resynchronization treatment.

Authors:  Tasneem Z Naqvi; Asim M Rafique; C Thomas Peter
Journal:  Cardiovasc Ultrasound       Date:  2006-10-18       Impact factor: 2.062

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.